Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736231 | 0.93 | CYP3A4 (0.66) | CYP3A4 | |
| SCHEMBL2736188 | 0.93 | CYP3A4 (0.66) | CYP3A4 | |
| SCHEMBL10067531 | 0.93 | CYP3A4 (0.66) | CYP3A4 | |
| SCHEMBL18715783 | 0.93 | CYP3A4 (0.66) | CYP3A4 | |
| SCHEMBL18893338 | 0.92 | CYP3A4 (0.67) | CYP3A4 | |
| SCHEMBL2736215 | 0.91 | CYP3A4 (0.59) | CYP3A4CYP2D6 | |
| SCHEMBL18715751 | 0.86 | CYP3A4 (0.73) | CYP3A4 | |
| SCHEMBL2736036 | 0.86 | CYP3A4 (0.73) | CYP3A4 | |
| SCHEMBL21946528 | 0.86 | CYP3A4 (0.73) | CYP3A4 | |
| SCHEMBL2736101 | 0.86 | CYP3A4 (0.73) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.